Cited 7 times in
Outcome of adefovir add-on lamivudine rescue therapy of up to 5 years in patients with lamivudine-resistant chronic hepatitis B
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김도영 | - |
dc.contributor.author | 김범경 | - |
dc.contributor.author | 김성배 | - |
dc.contributor.author | 김승업 | - |
dc.contributor.author | 박준용 | - |
dc.contributor.author | 안상훈 | - |
dc.contributor.author | 한광협 | - |
dc.date.accessioned | 2017-02-24T03:43:09Z | - |
dc.date.available | 2017-02-24T03:43:09Z | - |
dc.date.issued | 2016 | - |
dc.identifier.issn | 0815-9319 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/146424 | - |
dc.description.abstract | BACKGROUND AND AIM: We investigated the long-term efficacy of adefovir add-on lamivudine rescue therapy in lamivudine-resistant chronic hepatitis B and the optimal cutoff hepatitis B virus (HBV) DNA level that predicts complete virological response (CVR) among patients without CVR after 1 year of treatment. METHODS: We reviewed 167 lamivudine-resistant chronic hepatitis B patients who received adefovir add-on rescue therapy for up to 5 years. Multivariate analysis, area under the receiver operating characteristic curves, and Youden index were used. RESULTS: Median age was 47.0 years; 112 patients were male. Median baseline HBV DNA level was 6.6 log10 IU/mL; hepatitis B e antigen was positive in 130 (77.4%) patients. Five-year CVR, alanine aminotransferase normalization, hepatitis B e antigen seroconversion, and adefovir resistance rates were 86.9%, 92.5%, 16.7%, and 6.0%, respectively. One-year HBV DNA level independently associated with CVR. Optimal cutoff HBV DNA level to predict CVR among patients who failed to achieve CVR at 1 year was 800 IU/mL (area under receiver operating characteristic curve 0.752; sensitivity 49.3%, specificity 93.5%). During the 5-year treatment, 92.1% of patients with favorable response (HBV DNA < 800 IU/mL at 1 year) achieved CVR; 45.6% achieved CVR among suboptimal responders (HBV DNA ≥ 800 IU/mL at 1 year) (P < 0.001). CONCLUSION: Complete virological response or HBV DNA level < 800 IU/mL after 1 year adefovir add-on lamivudine rescue therapy can favorably predict CVR. | - |
dc.description.statementOfResponsibility | restriction | - |
dc.format.extent | 241~247 | - |
dc.language | English | - |
dc.publisher | Blackwell Scientific Publications | - |
dc.relation.isPartOf | JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.subject.MESH | Adenine/administration & dosage | - |
dc.subject.MESH | Adenine/analogs & derivatives* | - |
dc.subject.MESH | Alanine Transaminase/blood | - |
dc.subject.MESH | Antiviral Agents/administration & dosage* | - |
dc.subject.MESH | Biomarkers/blood | - |
dc.subject.MESH | DNA, Viral/blood | - |
dc.subject.MESH | Drug Resistance, Viral | - |
dc.subject.MESH | Drug Therapy, Combination | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Hepatitis B e Antigens/blood | - |
dc.subject.MESH | Hepatitis B virus/genetics | - |
dc.subject.MESH | Hepatitis B, Chronic/diagnosis | - |
dc.subject.MESH | Hepatitis B, Chronic/drug therapy* | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Lamivudine/administration & dosage* | - |
dc.subject.MESH | Male | - |
dc.subject.MESH | Middle Aged | - |
dc.subject.MESH | Multivariate Analysis | - |
dc.subject.MESH | Organophosphonates/administration & dosage* | - |
dc.subject.MESH | ROC Curve | - |
dc.subject.MESH | Time Factors | - |
dc.subject.MESH | Treatment Outcome | - |
dc.title | Outcome of adefovir add-on lamivudine rescue therapy of up to 5 years in patients with lamivudine-resistant chronic hepatitis B | - |
dc.type | Article | - |
dc.publisher.location | Australia | - |
dc.contributor.college | College of Medicine | - |
dc.contributor.department | Dept. of Internal Medicine | - |
dc.contributor.googleauthor | Sung Bae Kim | - |
dc.contributor.googleauthor | Seung Up Kim | - |
dc.contributor.googleauthor | Beom Kyung Kim | - |
dc.contributor.googleauthor | Jun Yong Park | - |
dc.contributor.googleauthor | Do Young Kim | - |
dc.contributor.googleauthor | Sang Hoon Ahn | - |
dc.contributor.googleauthor | Kwang-Hyub Han | - |
dc.identifier.doi | 10.1111/jgh.13046 | - |
dc.contributor.localId | A00385 | - |
dc.contributor.localId | A00487 | - |
dc.contributor.localId | A00570 | - |
dc.contributor.localId | A00654 | - |
dc.contributor.localId | A01675 | - |
dc.contributor.localId | A02226 | - |
dc.contributor.localId | A04268 | - |
dc.relation.journalcode | J01417 | - |
dc.identifier.eissn | 1440-1746 | - |
dc.identifier.pmid | 26204913 | - |
dc.identifier.url | http://onlinelibrary.wiley.com/doi/10.1111/jgh.13046/abstract | - |
dc.subject.keyword | adefovir | - |
dc.subject.keyword | chronic hepatitis B | - |
dc.subject.keyword | combination therapy | - |
dc.subject.keyword | complete virological response | - |
dc.subject.keyword | lamivudine resistance | - |
dc.contributor.alternativeName | Kim, Do Young | - |
dc.contributor.alternativeName | Kim, Beom Kyung | - |
dc.contributor.alternativeName | Kim, Sung Bae | - |
dc.contributor.alternativeName | Kim, Seung Up | - |
dc.contributor.alternativeName | Park, Jun Yong | - |
dc.contributor.alternativeName | Ahn, Sang Hoon | - |
dc.contributor.alternativeName | Han, Kwang Hyup | - |
dc.contributor.affiliatedAuthor | Kim, Do Young | - |
dc.contributor.affiliatedAuthor | Kim, Beom Kyung | - |
dc.contributor.affiliatedAuthor | Kim, Sung Bae | - |
dc.contributor.affiliatedAuthor | Kim, Seung Up | - |
dc.contributor.affiliatedAuthor | Park, Jun Yong | - |
dc.contributor.affiliatedAuthor | Ahn, Sang Hoon | - |
dc.contributor.affiliatedAuthor | Han, Kwang Hyup | - |
dc.citation.volume | 31 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 241 | - |
dc.citation.endPage | 247 | - |
dc.identifier.bibliographicCitation | JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, Vol.31(1) : 241-247, 2016 | - |
dc.date.modified | 2017-02-24 | - |
dc.identifier.rimsid | 48412 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.